Ann: Nyrada Quarterly Activities Report & Appendix 4C, page-6

Market doesn't like delays (Or Biotech's at the moment - its all battery metals).

NYR have been quite transparent with timelines and there is no material change in todays Qtly.

Fully funded through the trials is fantastic (already known) - but good to reiterate as no cap raise risk holding it back leading into commencement of trials..

As early stage biotechs go, the PCSK-9 trial presents a very attractive risk reward proposition (high probability of favourable trial results and low mkt cap).

Efficacy from mouse models for statins and prior PCSK-9 studies translated very well to human trials, Efficacy is not likely to be an issue at all... So it really is a safety trial with a qn on how big is the reduction in LDL.